Advancements of artificial intelligence into pharma research present opportunities for more efficient recruitment and enrollment processes for clinical trial stakeholders, while at the same time giving patients and caregivers greater access to research treatment options. Worldwide Clinical Trials, in its new partnership with Deep Lens, is pioneering efforts in AI-driven patient recruitment in oncology research.
Advancements of AI into pharma research present opportunities for more efficient recruitment and enrollment processes for clinical trial stakeholders, while at the same time giving patients and caregivers greater access to research treatment options. Worldwide Clinical Trials, in its new partnership with Deep Lens, is pioneering efforts in AI-driven patient recruitment in oncology research.
The patient-recruitment stage, a critical point in clinical trials, requires a hefty investment of time and money simply to get a study off the ground. Adding further risk to this resource-intensive stage is the likelihood of further recruitment efforts at a later stage of the trial, should those original patients fail to comply or meet critical endpoints. For oncology studies in particular, it is estimated that only 3% of all qualifying patients are participating oncology clinical trials, despite the potential benefits these patients stand to gain by participation in such trials.1 This low percentage indicates a huge untapped pool of potential study subjects, patients who stand to benefit personally from participation in a clinical trial while at the same time supporting advances in cancer treatment.
Here are just a few ways artificial intelligence can enhance patient recruitment efforts for clinical trials:
- Integration of AI technologies with electronic medical care records enables precision diagnosis and identification of potential study recruits faster than any current methods.
- Real-time diagnosis with identification of complex oncology subtypes and stages enables more sophisticated approaches to achieving heterogeneity of patient cohorts.
- Earlier identification of patient suitability for trials provides timely opportunities for physicians to discuss clinical research as a care option with qualifying patients.
- A streamlined process of recruitment promotes engagement between industry stakeholders and patients with their support networks, which can prove beneficial at the evaluation and approval stage.
For those executing drug development programs, the integration of AI technologies with current research processes presents the potential for fast-tracked recruitment with more precision in patient selection. These added efficiencies in the enrollment process can potentially reduce study timelines and promote stronger data, all of which adds up to improved chances of study success and lower costs for sponsors. With AI-driven coordination of patients and their support networks with scientific and industry stakeholders, the enhanced engagement can create a system of layperson support and advocacy to bring added momentum to evaluation and approval timelines.
Worldwide Clinical Trials has recently partnered with Deep Lens to explore new possibilities for integration of artificial intelligence technology in clinical trial execution. A new pilot study will pair innovative clinical trial design with Deep Lens’s VIPER patient identification platform to enhance study recruitment through real-time diagnosis and active identification of suitable study candidates. Worldwide and Deep Lens believe that this partnership will create a new model for clinical trial design and execution, thus laying the groundwork for further learnings around AI-driven medical research.
Uncommon Conversations with Worldwide Clinical Trials
About Deep Lens
Deep Lens is a technology company focused on a truly groundbreaking approach to faster recruitment of the best-suited cancer patients for clinical trials. VIPER, Deep Lens’ integrated cloud platform, identifies patients at the time of cancer diagnosis, providing care teams visibility and alerting capabilities of all available trials accelerating recruitment to bring game-changing therapies to market sooner so that patients can get the therapies they want and deserve. Based in Columbus Ohio, Deep Lens is growing with major biopharma, provider and strategic partners to challenge the clinical trial recruitment status quo and has been named most recently to the inaugural Digital Health 150 ranking, showcasing the 150 most promising private digital health companies in the world and the 90+ Startups in Healthcare by CB Insights. For more information, visit deeplens.ai or connect with Deep Lens on LinkedIn and Twitter @DeepLens_AI.